Mufg Securities Americas Inc. Has $3.02 Million Stock Holdings in Stryker Corporation $SYK

Mufg Securities Americas Inc. raised its stake in shares of Stryker Corporation (NYSE:SYK) by 25.4% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,622 shares of the medical technology company’s stock after buying an additional 1,543 shares during the period. Mufg Securities Americas Inc.’s holdings in Stryker were worth $3,015,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of SYK. Brighton Jones LLC increased its position in Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after purchasing an additional 609 shares during the last quarter. Venturi Wealth Management LLC grew its stake in shares of Stryker by 4.0% in the 1st quarter. Venturi Wealth Management LLC now owns 1,861 shares of the medical technology company’s stock valued at $693,000 after buying an additional 72 shares in the last quarter. AE Wealth Management LLC increased its holdings in Stryker by 6.7% in the first quarter. AE Wealth Management LLC now owns 2,317 shares of the medical technology company’s stock worth $863,000 after buying an additional 146 shares during the last quarter. Pinnacle Associates Ltd. raised its position in Stryker by 0.3% during the first quarter. Pinnacle Associates Ltd. now owns 13,961 shares of the medical technology company’s stock valued at $5,197,000 after acquiring an additional 40 shares in the last quarter. Finally, Advisor OS LLC lifted its stake in Stryker by 17.8% in the first quarter. Advisor OS LLC now owns 775 shares of the medical technology company’s stock valued at $288,000 after acquiring an additional 117 shares during the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 276,173 shares of the company’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the completion of the transaction, the director directly owned 2,702,108 shares in the company, valued at $954,600,714.24. This represents a 9.27% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Viju Menon sold 500 shares of the stock in a transaction on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the sale, the insider directly owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. This trade represents a 3.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 522,618 shares of company stock worth $185,577,237. 5.90% of the stock is owned by insiders.

Stryker Trading Up 2.2%

Stryker stock opened at $368.35 on Friday. Stryker Corporation has a 52 week low of $329.16 and a 52 week high of $406.19. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The firm has a market capitalization of $140.87 billion, a PE ratio of 48.79, a PEG ratio of 2.66 and a beta of 0.94. The business’s 50-day simple moving average is $369.38 and its 200-day simple moving average is $380.68.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, beating the consensus estimate of $3.13 by $0.06. The firm had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $6.04 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.87 EPS. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Equities research analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have recently commented on SYK. Truist Financial increased their price target on shares of Stryker from $392.00 to $400.00 and gave the stock a “hold” rating in a research note on Friday, November 14th. Needham & Company LLC reissued a “buy” rating and set a $448.00 target price on shares of Stryker in a research report on Friday, November 14th. Evercore ISI reduced their price target on Stryker from $410.00 to $405.00 and set an “outperform” rating for the company in a research report on Friday, October 31st. Rothschild Redb upgraded Stryker to a “hold” rating in a research note on Thursday, September 18th. Finally, Rothschild & Co Redburn initiated coverage on Stryker in a research note on Thursday, September 18th. They issued a “neutral” rating and a $420.00 price objective on the stock. Thirteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $434.37.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.